Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chan, S. L. [1 ]
Miksad, R. [2 ]
Cicin, I. [3 ]
Chen, Y. [4 ]
Klumpen, H. J. [5 ]
Kim, S. [6 ]
Lin, Z. Z. [7 ]
Youkstetter, J. [8 ]
Sen, S. [8 ]
Cheng, A-L. [9 ]
El-Khoueiry, A. B. [10 ]
Meyer, T. [11 ]
Kelley, R. K. [12 ]
Abou-Alfa, G. K. [13 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol South China, Hong Kong, Peoples R China
[2] Beth Israel Deaconess Med Ctr, Res Oncol, New York, NY USA
[3] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[4] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[5] AMC, Med Oncol, Amsterdam, Netherlands
[6] Ctr Hosp Reg Univ Besancon, Med Oncol, Besancon, France
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Exelixis Inc, Dept Oncol, Alameda, CA USA
[9] Natl Taiwan Univ Hosp, Canc Ctr, Taipei, Taiwan
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[11] UCL, Dept Oncol, London, England
[12] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, Dept Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
127P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    El-Khoueiry, A. B.
    Meyer, T.
    Rimassa, L.
    Merle, P.
    Chan, S. L.
    Tran, A.
    Parnis, F.
    Tam, V. C.
    Cattan, S.
    Markby, D. W.
    Clary, D. O.
    Cheng, A-L.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] RAMUCIRUMAB AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: ANALYSIS OF REACH PATIENTS BY ALBUMIN-BILIRUBIN (ALBI) GRADE
    Blanc, J. -F.
    Chan, S. L.
    Park, J. O.
    Ryoo, B. -Y.
    Yen, C. -J.
    Kudo, M.
    Poon, R.
    Pastorelli, D.
    Baron, A.
    Pfiffer, T. F.
    Okusaka, T.
    Kubackova, K.
    Trojan, J.
    Sastre, J.
    Chau, I.
    Abada, P.
    Chang, S. -C.
    Yang, L.
    Zhu, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S693 - S694
  • [23] Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Suzuki, Eiichiro
    Kanogawa, Naoya
    Saito, Tomoko
    Motoyama, Tenyu
    Tawada, Akinobu
    Kanai, Fumihiko
    Yokosuka, Osamu
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1257 - 1262
  • [24] Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Meyer, T.
    Cheng, A.
    Cicin, I.
    Bolondi, L.
    Klumpen, H.
    Chan, S.
    Zagonel, V.
    Milwee, S.
    Dubey, S.
    Kelley, R.
    El-Khoueiry, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 33 - 34
  • [25] Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Parnis, F.
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Blanc, J. F.
    Lim, H-Y
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 180 - 181
  • [26] An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria
    Ho, Shu-Yein
    Liu, Po-Hong
    Hsu, Chia-Yang
    Hsia, Cheng-Yuan
    Su, Chien-Wei
    Huang, Yi-Hsiang
    Lei, Hao-Jan
    He, Yi-Jhen
    Hou, Ming-Chih
    Huo, Teh-Ia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (09): : 698 - 704
  • [27] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade
    Ho, Shu-Yein
    Yuan, Mei-Hsia
    Liu, Po-Hong
    Hsu, Chia-Yang
    Huang, Yi-Hsiang
    Liao, Jia-, I
    Su, Chien-Wei
    Wang, Chia-Lin
    Hou, Ming-Chih
    Huo, Teh-la
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (01) : 61 - 69
  • [29] Integration of Albumin-Bilirubin (ALBI) score into current tumour staging system for hepatocellular carcinoma (HCC)
    Chan, S. L.
    To, K. F.
    Mo, F.
    Chong, C. C. N.
    Yeo, W.
    Johnson, P.
    Lai, P.
    Chan, A. W. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S414 - S414
  • [30] Prognostic Value of Albumin-Bilirubin Grade (ALBI) in Patients Underwent Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
    Khalid, Muhammad Ali
    Khan, Inamullah
    Khan, Shoaib Ahmed
    Majid, Zain
    Hanif, Farina
    Iqbal, Jawaid
    Laeeq, Syed Mudassir
    Luck, Nasir
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S484 - S484
12345